Loading...
Please wait, while we are loading the content...
Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
| Content Provider | Scilit |
|---|---|
| Author | Nomura, Shosaku Dan, Kazuo Hotta, Tomomitsu Fujimura, Kingo Ikeda, Yasuo |
| Copyright Year | 2002 |
| Description | We conducted a phase 1-2 clinical trial to evaluate the effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with chronic idiopathic thrombocytopenic purpura (ITP) refractory to standard therapy who had platelet counts below 30 × $10^{9}$/L. Four patients received PEG-rHuMGDF (0.5 μg/kg of body weight per day) by daily intravenous injection for up to 7 days. Administration of PEG-rHuMGDF increased platelet counts in 3 patients. A striking thrombocytosis occurred in 2 patients, whose platelet counts were elevated to more than 700 × $10^{9}$/L a week after the last administration of PEG-rHuMGDF and returned to baseline levels within 4 to 6 weeks. Before the platelet peak, the percentage of reticulated platelets increased transiently in 3 patients tested, including one patient who had no response. Bleeding episodes decreased after the start of PEG-rHuMGDF therapy. These results suggest that PEG-rHuMGDF might have a clinical benefit in ameliorating thrombocytopenia associated with ITP. |
| Related Links | http://www.bloodjournal.org/content/bloodjournal/100/2/728.full.pdf |
| Ending Page | 730 |
| Page Count | 3 |
| Starting Page | 728 |
| DOI | 10.1182/blood.v100.2.728 |
| Journal | Blood |
| Issue Number | 2 |
| Volume Number | 100 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2002-06-28 |
| Access Restriction | Open |
| Subject Keyword | Hematology Purpura Idiopathic Administration Recombinant Megakaryocyte Thrombocytopenic Pegylated Platelet Counts Peg Rhumgdf Journal: Blood (Vol- 59, Issue- 2) |
| Content Type | Text |
| Resource Type | Article |